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agree that dose reduction is a reasonable option 
and one that may be associated with continued 
clinical benefit.
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Early versus On-Demand Tube Feeding in Pancreatitis
To the Editor: Bakker et al. (Nov. 20 issue)1 
found no benefit of early enteral nutrition in pa-
tients with predicted severe acute pancreatitis. 
Clinical trials involving patients with this condi-
tion are hampered by the low positive predictive 
value of current prognostic scoring systems, re-
sulting in the inclusion of many patients who 
ultimately have mild acute pancreatitis and do 
not require early enteral nutrition.2 A composite 
end point allowed for sample-size reduction but 
ultimately resulted in an underpowered study, 
owing to the inequality between the individual 
end points.3 Death and infection have vastly dif-
ferent clinical significance, given that persistent 
organ failure, not infection, is the primary cause 
of death in patients with severe acute pancreati-
tis.4,5 The timing, type, and volume of fluid ad-
ministered were not detailed in this study. Indi-
vidual centers across this consortium may have 
different practices with regard to fluid resuscita-
tion that potentially biased the results toward the 
null hypothesis. Enteral nutrition has consistent-
ly been shown to have a benefit in patients with 
severe acute pancreatitis, but we are still no closer 
to optimizing patient selection and the timing of 
enteral nutrition.
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To the Editor: The study by Bakker et al. requires 
careful interpretation. First, the actual delivery 
site of enteral nutrition is unclear. The authors 
did not disclose in the article that the original 
ethics committee approval was for tube feeding 
into the stomach, not the jejunum. Furthermore, 
feeding tubes were dislodged in 40% of the pa-
tients, which many would consider to be a rather 
high rate for leading research centers. Second, 
only one third of the study patients had actual, as 
opposed to predicted, severe or critical acute 
pancreatitis (i.e., persistent organ failure, infect-
ed pancreatic necrosis, or both).1 Hence, two 
thirds of the patients in the study were not posed 
to benefit from tube feeding.2 Third, the lack of 
superiority of feeding within 24 hours after pre-
sentation versus feeding at 72 hours (or later) af-
ter presentation does not mean that the latter 
should be deemed the preferred nutritional strat-
egy. The weight of evidence indicates that the 
most effective time to start feeding in patients 
with acute pancreatitis is between 24 and 72 
hours after presentation, and the exact timing of 
feeding in an individual patient is influenced by 
the adequacy of intravenous fluid resuscitation 
and opiate use.3-5
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The Authors Reply: The limited accuracy of 
prognostic scoring systems in acute pancreatitis 
is addressed in the letters by Moran et al. and by 
Petrov and Windsor. However, currently there is 
no better tool available during triage, when clini-
cians need to make decisions regarding any type 
of early intervention. This limitation does not 
undermine the validity of the study results. The 
sample size was estimated on the basis of studies 
that used similar predictive scoring systems in 
similar patient populations with similar clinical 
outcomes.1 Furthermore, this approach reflects 
how clinical decision making for patients with 
acute pancreatitis is done in everyday practice 
and therefore, in our opinion, is relevant to prac-
ticing clinicians.
Moran et al. question the composition of the 
primary end point. Our study was designed to 
show a reduction in the rate of infection because 
infection has a major effect on the outcome of 
patients with acute pancreatitis.2 No significant 
differences were found in the individual compo-
nents of the primary end point, which strongly 
suggests that the proposed inequality does not 
hamper the overall power of the study.
In the complex setting of a large, multicenter 
trial, subtle differences in treatment among cen-
ters may occur, including with regard to fluid 
resuscitation. However, a randomized study de-
sign and stratification according to study center 
balance out such differences between treatment 
groups.
In response to Petrov and Windsor: the first 
version of the protocol indeed included nasogas-
tric instead of nasojejunal feeding. After critical 
appraisal of the available evidence at the time, 
we decided to switch to nasojejunal feeding to 
minimize the risk of aspiration. This decision 
was made before the start of patient recruitment 
and hence did not influence outcome (for details, 
see www.isrctn.com/ISRCTN18170985). The rate 
of tube dislocation is similar to rates found in 
the literature.3,4
Our study did not show that starting an oral 
diet 72 hours after presentation is the most ef-
fective strategy for all patients with acute pan-
creatitis. However, our results show that routine 
early tube feeding in all patients at high risk for 
severe pancreatitis does not improve outcome 
and that the implementation of on-demand tube 
feeding will reduce patient discomfort and costs.
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High-Cost Generic Drugs — Implications for Patients and Policymakers
To the Editor: The Perspective article by Alpern 
et al. (Nov. 13 issue)1 states that manufacturers 
of new generic drugs can have delays before the 
Office of Generic Drugs of the Food and Drug 
Administration (FDA) approves their products. 
Over the years, the increasing number of applica-
tions submitted to the FDA for the review of ge-
neric drugs resulted in a backlog that drove the 
establishment of the Generic Drug User Fee 
Amendments (GDUFA) of 2012.2 The GDUFA 
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